Appendix 3B

New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity

WEEBIT NANO LTD

ABN

15 146 455 576

We (the entity) give ASX the following information.

Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

+Class of +securities issued or to 1 Ordinary shares be issued 2 Number of +securities issued or 14,333,334 to be issued (if known) or maximum number which may be issued Principal terms of the +securities Conversion of Unlisted Options – with an 3 (eg, if options, exercise price and exercise price of \$0.03 - expiring 30 June expiry date; if partly paid 2020 to Ordinary shares. +securities, the amount outstanding and due dates for if +convertible payment; securities, the conversion price and dates for conversion)

⁺ See chapter 19 for defined terms.

4	 Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities? If the additional securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	Yes - Ordinary Shares issued rank pari passu with existing shares on issue.
5	Issue price or consideration	\$0.03 per Unlisted Option
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	Certain optionholders have exercised their options under the terms of the issue. Funds received from this exercise will be used by the Company for the continued development of its technology and for general working capital purposes.
6a	Is the entity an ⁺ eligible entity that has obtained security holder approval under rule 7.1A? If Yes, complete sections 6b – 6h <i>in relation to the</i> ⁺ <i>securities the</i> <i>subject of this Appendix 3B</i> , and comply with section 6i	Yes
6b	The date the security holder resolution under rule 7.1A was passed	30 November 2016
6с	Number of *securities issued without security holder approval under rule 7.1	Not Applicable

⁺ See chapter 19 for defined terms.

- 6d Number of +securities issued with security holder approval under rule 7.1A
- 6e Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)
- 6f Number of securities issued under an exception in rule 7.2
- 6g If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.
- 6h If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
- 6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements
- 7 Dates of entering ⁺securities into uncertificated holdings or despatch of certificates
- 8 Number and ⁺class of all ⁺securities quoted on ASX (*including* the securities in section 2 if applicable)

814,628,100	Ordinary fully paid shares

Not applicable

Not applicable

14,333,334

Not applicable

Not applicable

7.1 – 7,311,151 7.1A – 7,101,486

24 November 2017

⁺ See chapter 19 for defined terms.

		Number	+Class
9	Number and ⁺ class of all	576,355,785	Ordinary shares
	⁺ securities not quoted on ASX (<i>including</i> the securities in section 2 if applicable)	17,304,545	Performance Rights
		5,000,000	Options - Exercise price
		0,000,000	\$0.05, expiry 16 Sept 2018
		50 000 000	
		50,000,000	Options - Exercise price
			\$0.0625, expiry 1 Aug 2019
		76,258,998	Options – Exercise price
			\$0.03, expiry 30 June 2020
10	Dividend policy (in the case of a	Ν/Δ	

10 Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)

a N/A ne

Part 2 - Bonus issue or pro rata issue

Questions 11 to 33 not applicable

Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- 34 Type of securities (*tick one*)
 - Securities described in Part 1
- (b)

(a)

All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Entities that have ticked box 34(a)

Questions 35 to 37not applicable

⁺ See chapter 19 for defined terms.

Entities that have ticked box 34(b)

38	Number of securities for which ⁺ quotation is sought	14,333,334	
39	Class of <i>*securities</i> for which quotation is sought	Ordinary Shares	
40	 Do the *securities rank equally in all respects from the date of allotment with an existing *class of quoted *securities? If the additional securities do not rank equally, please state: the date from which they do the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment 	Yes	
41	Reason for request for quotation now (if issued upon conversion of another security, clearly identify that other security)	Partial exercise of Unlist 25 October 2017, with a \$0.03 and an expiry of 3	an exercise price of
		Number	+Class

42 Number and *class of all *securities quoted on ASX (*including* the securities in clause 38)

Number	+Class
814,628,100	Ordinary Shares

⁺ See chapter 19 for defined terms.

Quotation agreement

- +Quotation of our additional +securities is in ASX's absolute discretion.
 ASX may quote the +securities on any conditions it decides.
- 2 We warrant the following to ASX.
 - The issue of the ⁺securities to be quoted complies with the law and is not for an illegal purpose.
 - There is no reason why those *securities should not be granted *quotation.
 - An offer of the ⁺securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any *securities to be quoted and that no-one has any right to return any *securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the *securities be quoted.
- If we are a trust, we warrant that no person has the right to return the ⁺securities to be quoted under section 1019B of the Corporations Act at the time that we request that the ⁺securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- 4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

Company Secretary

Date: 24 November 2017

Print name: Mark Licciardo

⁺ See chapter 19 for defined terms.

Appendix 3B – Annexure 1

1.1 Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

1.2 Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
<i>Insert</i> number of fully paid ⁺ ordinary securities on issue 12 months before the ⁺ issue date or date of agreement to issue	1,168,076,215	
Add the following:		
 Number of fully paid ⁺ordinary securities issued in that 12 month period under an exception in rule 7.2 	7,500,000 (Exception 4) $-$ 05/12/2016 13,333,334 (Exception 4) $-$ 08/11/2017 7,741,000 (Exception 4) $-$ 09/11/2017 13,333,334 (Exception 4) $-$ 14/11/2017 14,333,334 (Exception 4) $-$ 24/11/2017	
 Number of fully paid ⁺ordinary securities issued in that 12 month period with shareholder approval 	NA	
 Number of partly paid ⁺ordinary securities that became fully paid in that 12 month period 		
 Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
<i>Subtract</i> the number of fully paid ⁺ ordinary securities cancelled during that 12 month period	NA	
"A"	1,224,317,217	

⁺ See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"В"	0.15 [Note: this value cannot be changed]	
<i>Multiply</i> "A" by 0.15	183,647,583	
Step 3: Calculate "C", the amount 7.1 that has already been used	of placement capacity under rule	
<i>Insert</i> number of ⁺ equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	51,336,432 Ordinary Shares 125,000,000 Unlisted Options	
Under an exception in rule 7.2		
Under rule 7.1A		
• With security holder approval under rule 7.1 or rule 7.4		
 Note: This applies to equity securities, unless specifically excluded – not just ordinary securities Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items 		
"C"	176,336,432	
Step 4: Subtract "C" from ["A" x " placement capacity under rule 7.1		
"A" x 0.15	183,647,583	
Note: number must be same as shown in Step 2		
Subtract "C"	176,336,432	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	7,311,151	
	[Note: this is the remaining placement capacity under rule 7.1]	

⁺ See chapter 19 for defined terms.

1.3 Part 2

Rule 7.1A – Additional placement capacity for eligible entities Step 1: Calculate "A", the base figure from which the placement capacity is calculated			
			"A"
Note: number must be same as shown in Step 1 of Part 1			
Step 2: Calculate 10% of "A"			
"D"	0.10		
	Note: this value cannot be changed		
<i>Multiply</i> "A" by 0.10	122,431,722		
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used			
<i>Insert</i> number of ⁺ equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	115,330,236		
Notes: • This applies to equity securities – not just ordinary securities			
 Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed 			
• Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security			
 holder approval has been obtained It may be useful to set out issues of securities on different dates as 			
separate line items "F"	115,330,236		

⁺ See chapter 19 for defined terms.

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10 Note: number must be same as shown in Step 2	122,431,722	
<i>Subtract</i> "E" Note: number must be same as shown in Step 3	115,330,236	
<i>Total</i> ["A" x 0.10] – "E"	7,101,486 Note: this is the remaining placement capacity under rule 7.1A	

Г

⁺ See chapter 19 for defined terms.